Lucie Ailhaud

Lucie Ailhaud

Infectious disease, APHM, CHU Timone, Marseille, France, Marseille, Provence-Alpes-Côte d’Azur, France
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
SASophie Amrane
Sophie Amrane
HTHervé Tissot-Dupont
Hervé Tissot-Dupont
BDBarbara Doudier
Barbara Doudier
CECarole Eldin
Carole Eldin
MHMarie Hocquart
Marie Hocquart
PGPhilippe Gautret
Philippe Gautret

1 March 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
JLJean Christophe Lagier
Jean Christophe Lagier
PCPhilippe Colson
Philippe Colson
HDHervé Tissot Dupont
Hervé Tissot Dupont
JSJérôme Salomon
Jérôme Salomon
BDBarbara Doudier
Barbara Doudier
PBPhilippe Brouqui
Philippe Brouqui

1 September 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
LALucie Ailhaud
Lucie Ailhaud
CMCléa Melenotte
Cléa Melenotte
SASandrine Aubert
Sandrine Aubert
CLCoralie L'OLlivier
Coralie L'OLlivier
CACamille Aubry
Camille Aubry
PPPhilippe Parola
Philippe Parola

Verified
Journal Article
Open access
PDF file
LALucie Ailhaud
Lucie Ailhaud
RGRobinson Gravier-Dumonceau
Robinson Gravier-Dumonceau
FAFlorent Arregle
Florent Arregle
SHSandrine Hubert
Sandrine Hubert
JCJean-Paul Casalta
Jean-Paul Casalta
FGFrédérique Gouriet
Frédérique Gouriet
Background: Infective endocarditis (IE) is a serious condition which is difficult to diagnose and to treat, both medically and surgically. Objectives: The objective of this study was to evaluate the impact of the SARS-CoV-2 pandemic on the management of patients with IE. Methods: We conducted a single-centre retrospective study including patients hospitalized for IE during the pandemic (Group 2) compared with the same period the year before (Group 1). We compared clinical, laboratory, imagery, therapeutic, and patient outcomes between the two groups. Results: A total of 283 patients were managed for possible or definite IE (164 in Group 1 and 119 in Group 2). There were more intravenous drug-related IE patients in Group 2 (p = 0.009). There was no significant difference in surgery including intra-cardiac device extraction (p = 0.412) or time to surgery (p = 0.894). The one-year mortality was similar in both groups (16% versus 17.7%, p = 0.704). The recurrence rate was not significantly different between the two groups (5.9% in Group 2 versus 9.1% in Group 1, p = 0.311). Conclusions: The SARS-CoV-2 pandemic did not appear to have had a negative impact on the management of patients with IE. Maintenance of the activities of the endocarditis team within the referral centre probably contributed to this result. Nevertheless, the high proportion of intravenous drug-addicted patients in the pandemic cohort suggests that the SARS-CoV-2 pandemic had a major psychosocial impact.